2015
DOI: 10.3109/17435390.2014.992487
|View full text |Cite
|
Sign up to set email alerts
|

Surfactant protein A (SP-A) inhibits agglomeration and macrophage uptake of toxic amine modified nanoparticles

Abstract: The lung provides the main route for nanomaterial exposure. Surfactant protein A (SP-A) is an important respiratory innate immune molecule with the ability to bind or opsonise pathogens to enhance phagocytic removal from the airways. We hypothesised that SP-A, like surfactant protein D, may interact with inhaled nanoparticulates, and that this interaction will be affected by nanoparticle (NP) surface characteristics. In this study, we characterise the interaction of SP-A with unmodified (U-PS) and amine-modifi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
23
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 29 publications
(24 citation statements)
references
References 53 publications
(73 reference statements)
1
23
0
Order By: Relevance
“…Comparing the adhesive interaction of SP-D and SP-A to A-PS revealed for SP-A only a weak surface adhesion, which implies that the observed cellular effects could not be directly related to protein association [89].…”
Section: The Interplay Between Pulmonary Surfactant and Nanoparticlesmentioning
confidence: 90%
“…Comparing the adhesive interaction of SP-D and SP-A to A-PS revealed for SP-A only a weak surface adhesion, which implies that the observed cellular effects could not be directly related to protein association [89].…”
Section: The Interplay Between Pulmonary Surfactant and Nanoparticlesmentioning
confidence: 90%
“…Images were acquired with a home-built CARS and SHG capable, multiphoton microscope setup (21). For SHG the 835nm pump beam served as the excitation.…”
Section: Methodsmentioning
confidence: 99%
“…Improvements could concern the exposure of the NPs, such as pre-incubation of the NPs with a more realistic biofluid prior to cell treatments. For instance, surfactant can be used in the case of lung models (McKenzie et al 2015;Raesch et al 2015) and for oral uptake the different consecutive pH values encountered along the stages of the gastro-intestinal tract can be simulated (Peters et al 2012). Furthermore, skin and lung models may be exposed at the airliquid interface (Stoehr et al 2015) while ingestion models could include a more realistic digestion fluid on one side.…”
Section: Accepted Manuscriptmentioning
confidence: 99%